These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 9730150)

  • 41. Assessment of disease activity in Graves' ophthalmopathy by orbital ultrasonography and clinical parameters.
    Gerding MN; Prummel MF; Wiersinga WM
    Clin Endocrinol (Oxf); 2000 May; 52(5):641-6. PubMed ID: 10792345
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Serum levels of soluble Fas in patients with Graves' ophthalmopathy.
    Ohtsuka K; Hashimoto M
    Br J Ophthalmol; 2000 Jan; 84(1):103-6. PubMed ID: 10611108
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Effects of external orbital radiotherapy on the oculomotor muscle in Graves disease].
    Maalouf T; Angioi-Duprez K; Beckendorff V; Malet T; George JL
    J Fr Ophtalmol; 1996; 19(12):748-54. PubMed ID: 9033899
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Place of radiotherapy in the treatment of Graves' orbitopathy.
    Beckendorf V; Maalouf T; George JL; Bey P; Leclere J; Luporsi E
    Int J Radiat Oncol Biol Phys; 1999 Mar; 43(4):805-15. PubMed ID: 10098436
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Graves' ophthalmopathy].
    Badelon I; Morax S
    Rev Prat; 2005 Jan; 55(2):183-6. PubMed ID: 15826000
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Ophthalmologic aspects of treating optic neuropathy during the course of Graves-Basedow disease].
    Mirkiewicz-Sieradzka B; Jakubowska B
    Przegl Lek; 2000; 57(6):318-20. PubMed ID: 11107863
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Radiotherapy of endocrine orbitopathy--state of the art].
    Prettenhofer U; Ramschak-Schwarzer S; Langmann A; Mayer R; Schedlbauer P; Hackl A
    Acta Med Austriaca; 2001; 28(4):97-8. PubMed ID: 11593899
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Extraocular muscle antibodies and the occurrence of ophthalmopathy in Graves' disease.
    de Bellis A; Perrino S; Coronella C; Sansone D; Ruocco G; Tirelli G; Di Martino S; Conte M; Bellastella G; Wall JR; Bellastella A; Bizzarro A
    Clin Endocrinol (Oxf); 2004 Jun; 60(6):694-8. PubMed ID: 15163332
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The role of radiation therapy in Graves' ophthalmopathy.
    Chowdhury AD; Moriarty MJ
    Australas Radiol; 1996 Nov; 40(4):422-3. PubMed ID: 8996904
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Radiotherapy for Graves' ophthalmopathy].
    Kuhnt T; Müller AC; Janich M; Gerlach R; Hädecke J; Duncker GI; Dunst J
    Klin Monbl Augenheilkd; 2004 Nov; 221(11):915-21. PubMed ID: 15562354
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The effect of somatostatin versus corticosteroid in the treatment of Graves' ophthalmopathy.
    Kung AW; Michon J; Tai KS; Chan FL
    Thyroid; 1996 Oct; 6(5):381-4. PubMed ID: 8936659
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Radiotherapy for Graves' ophthalmopathy: results at one year.
    Gorman CA
    Thyroid; 2002 Mar; 12(3):251-5. PubMed ID: 11952049
    [TBL] [Abstract][Full Text] [Related]  

  • 53. New immunomodulators in the treatment of Graves' ophthalmopathy.
    Salvi M; Vannucchi G; Campi I; Currò N; Beck-Peccoz P
    Ann Endocrinol (Paris); 2008 Apr; 69(2):153-6. PubMed ID: 18417090
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Surgical or medical decompression as a first-line treatment of optic neuropathy in Graves' ophthalmopathy? A randomized controlled trial.
    Wakelkamp IM; Baldeschi L; Saeed P; Mourits MP; Prummel MF; Wiersinga WM
    Clin Endocrinol (Oxf); 2005 Sep; 63(3):323-8. PubMed ID: 16117821
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Practical Guidelines Management of Graves Ophthalmopathy.
    Subekti I; Soewondo P; Soebardi S; Darmowidjojo B; Harbuwono DS; Purnamasari D; Tarigan TJE; Wisnu W; Tahapary DL; Kurniawan F; Sidik M; Nusanti S; Dewiputri S; Suharko H; Suardana GG; Suroyo I; Wulani V; Siswoyo AD; Gondhowiardjo S; Kodrat H
    Acta Med Indones; 2019 Oct; 51(4):364-371. PubMed ID: 32041923
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Comparative Efficacy of Four Treatments in Patients with Graves' Disease: a Network Meta-analysis.
    Ren Z; Qin L; Wang JQ; Li Y; Li J; Zhang RG
    Exp Clin Endocrinol Diabetes; 2015 May; 123(5):317-22. PubMed ID: 25988881
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Treatment of Graves' ophthalmopathy by steroid therapy, orbital radiation therapy, plasmapheresis and thyroxine replacement.
    Yamamoto K; Saito K; Takai T; Yoshida S
    Endocrinol Jpn; 1982 Aug; 29(4):495-501. PubMed ID: 6897533
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Intravenous immunoglobulin versus corticosteroid in treatment of Graves' ophthalmopathy.
    Baschieri L; Antonelli A; Nardi S; Alberti B; Lepri A; Canapicchi R; Fallahi P
    Thyroid; 1997 Aug; 7(4):579-85. PubMed ID: 9292946
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Supervoltage radiotherapy for Graves' ophthalmopathy: CCABC technique and results.
    Olivotto IA; Ludgate CM; Allen LH; Rootman J
    Int J Radiat Oncol Biol Phys; 1985 Dec; 11(12):2085-90. PubMed ID: 3840786
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The management of ophthalmic Graves' disease.
    Leone CR
    Ophthalmology; 1984 Jul; 91(7):770-9. PubMed ID: 6548005
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.